rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.
|
25656898 |
2015 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.
|
23317446 |
2013 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
22972589 |
2013 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.
|
23237741 |
2013 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
|
23918947 |
2013 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
|
23248257 |
2013 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
|
22972589 |
2013 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
|
22735384 |
2012 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
|
22356324 |
2012 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
|
22735384 |
2012 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
|
22048237 |
2012 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Improved survival with MEK inhibition in BRAF-mutated melanoma.
|
22663011 |
2012 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
|
22048237 |
2012 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Improved survival with MEK inhibition in BRAF-mutated melanoma.
|
22663011 |
2012 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
22805292 |
2012 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
|
22536370 |
2012 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
22805292 |
2012 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
23020132 |
2012 |
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
|
22356324 |
2012 |
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
21639808 |
2011 |